Recently, targeting programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) immune checkpoint inhibitors have led to major progress in cancer immunotherapy; resulting in positive outcomes in clinical trials across various solid malignancies, including gastric carcinomas [2, 3]. This evidence concerns the gene PDCD1 and gastric carcinoma.